一种基于正电子发射断层成像验证的实用数据驱动方法确定阿尔茨海默病脑脊液生物标志物截断值
研究提出一种新算法,通过脑脊液磷酸化tau高低水平确定β-淀粉样蛋白(Aβ)最佳截断值,再据此确定tau和磷酸化tau截断值,并与基于tau和淀粉样蛋白PET成像状态的参考方法(ADNI研究)比较,随后应用于10个大型临床队列。共纳入6922例有脑脊液生物标志物数据的患者(平均年龄70.6岁,女性51.0%)。在ADNI研究人群(n=497)中,算法分类与基于淀粉样蛋白/tau PET成像的分类一致性高,Cohen kappa系数在0.87至0.99之间。应用于10个大型队列(n=6425)时,AD患者比例范围为25.9%至43.5%。
要点
- 新算法先确定脑脊液磷酸化tau高低水平,再确定Aβ最佳截断值,进而确定tau和磷酸化tau截断值。
- 在ADNI人群(n=497)中,算法分类与淀粉样蛋白/tau PET分类一致性高,Cohen kappa系数0.87至0.99。
- 应用于10个大型队列(n=6425)时,AD患者比例范围为25.9%至43.5%。
核心结论
- 所提出的新颖实用方法确定AD脑脊液生物标志物截断值,不需要评估其他生物标志物或对患者临床诊断作出假设。
- 使用该标准化算法可能减少AD分类的异质性。
研究设计与样本
- 研究提出一种新算法,先识别脑脊液磷酸化tau的低水平和高水平以确定脑脊液β-淀粉样蛋白(Aβ)肽生物标志物的最佳截断值,再用这些Aβ截断值确定脑脊液tau和磷酸化tau标志物的截断值。
- 将算法与基于tau和淀粉样蛋白PET成像状态的参考方法(ADNI研究)比较,随后应用于10个大型临床队列。
- 共纳入6922例有脑脊液生物标志物数据的患者(平均[SD]年龄70.6[8.5]岁,女性51.0%)。
主要发现
- 在ADNI研究人群(n=497)中,基于该算法的分类与基于淀粉样蛋白/tau PET成像的分类之间一致性高,Cohen kappa系数在0.87至0.99之间。
- 将算法应用于10个大型患者队列(n=6425)时,AD患者比例范围为25.9%至43.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To elaborate a new algorithm to establish a standardized method to define cutoffs for CSF biomarkers of Alzheimer disease (AD) by validating the algorithm against CSF classification derived from PET imaging. METHODS: Low and high levels of CSF phosphorylated tau were first identified to establish optimal cutoffs for CSF β-amyloid (Aβ) peptide biomarkers. These Aβ cutoffs were then used to determine cutoffs for CSF tau and phosphorylated tau markers. We compared this algorithm to a reference method, based on tau and amyloid PET imaging status (ADNI study), and then applied the algorithm to 10 large clinical cohorts of patients. RESULTS: A total of 6,922 patients with CSF biomarker data were included (mean [SD] age: 70.6 [8.5] years, 51.0% women). In the ADNI study population (n = 497), the agreement between classification based on our algorithm and the one based on amyloid/tau PET imaging was high, with Cohen's kappa coefficient between 0.87 and 0.99. Applying the algorithm to 10 large cohorts of patients (n = 6,425), the proportion of persons with AD ranged from 25.9% to 43.5%. DISCUSSION: The proposed novel, pragmatic method to determine CSF biomarker cutoffs for AD does not require assessment of other biomarkers or assumptions concerning the clinical diagnosis of patients. Use of this standardized algorithm is likely to reduce heterogeneity in AD classification.
引用
- Dumurgier J, Sabia S, Zetterberg H, et al. A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology. 2022. PMID: 35970577. doi:10.1212/WNL.0000000000200735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。